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Abstract
Cutaneous  malignancies,  especially  malignant  melanoma, 
exhibit great genetic heterogeneity. As a result, some individuals 
and  families  have  particularly  increased  risk  due  to  genetic 
predisposition  to  the  disease. The  susceptibility  alleles  range 
from rarely occurring, heritable, high-risk variants to ubiquitously 
occurring  low-risk  variants. Although  until  now  the  focus  has 
been mostly towards the familial high-risk genes, the develop-
ment  of  genome-wide  association  studies  has  uncovered  a 
number  of  moderate-  to  low-risk  predisposition  alleles.  The 
ability  to  specifically  identify  genetic  variation  associated  with 
visible pigmentation traits and disease risk has provided a much 
richer view of the genetics of cutaneous malignancies. In this 
review, we provide an update on the recently identified risk loci. 
Existing clinical data, combined with vast genome information, 
will provide a better understanding of the biology of disease, 
and increased accuracy in risk prediction.
Introduction
Cutaneous malignancies such as highly invasive melanoma, 
and  the  keratinocyte  carcinomas,  such  as  basal  cell 
carcinoma (BCC) and squamous cell carcinoma (SCC), have 
become increasingly common in recent decades. According 
to the Surveillance, Epidemiology and End Results (SEER) 
program, it is estimated that 74,610 men and women will be 
diagnosed with skin cancer in 2009 in the United States, 
and mortality is estimated to be 11,590 (excluding BCC and 
SCC) [1]. For melanoma alone, the diagnosis is estimated to 
be 68,720, and 8,650 [2]. BCC is the most common type of 
skin cancer and accounts for 80% of all skin cancers. Nearly 
half of people with BCC have recurrent tumors within five 
years of development of the primary tumor.
Like  most  cancers,  the  risk  factors  for  cutaneous 
malignancies  include  both  genetic  and  environmental 
components.  The  notion  that  melanoma  has  a  genetic 
predisposition  was  first  put  forth  in  1820  by  William 
Norris, who claimed it has ‘a strong tendency to hereditary 
predisposition’  [3].  Later  studies  reported  correlation 
between  the  prevalence  of  familial  multiple  melanomas 
and the occurrence of ‘atypical nevi (moles)’, and they were 
described  as  familial  atypical  multiple-mole  melanoma 
(FAMMM)  syndrome  or  BK  mole  syndrome  [4,5]. 
Advances  in  linkage  analysis  in  the  late  1980s  to  early 
1990s directed much attention towards identifying high-
risk,  high-penetrance  loci  associated  with  familial  pre-
disposition  to  melanoma.  Several  groups  identified 
germline mutations of the p16INK4a (now cyclin-depen-
dent kinase inhibitor 2A, CDKN2A) gene on chromosome 
9p21,  and  established  the  molecular  basis  of  hereditary 
melanoma in a subset of melanoma-prone kindreds (high-
lighted  in  [6]).  Subsequently,  Zuo  and  colleagues  [7] 
identified heritable alterations in the CDK4 gene in a few 
families  that  lacked  germline  CDKN2A  mutations.  The 
mutation rates of high-risk heritable alleles are less prevalent, 
although the biological relevance of these mutations is well 
characterized (reviewed in [8-10]). A study in three continents 
including a large population demonstrated that mutations in 
CDKN2A loci account for disease susceptibility in 20 to 57% 
of all melanoma families [11].
With the completion of the Human Genome Project and 
the  HapMap  and  the  recognition  that  single  nucleotide 
polymorphisms (SNPs) are found in the genome at fixed 
locations,  it  became  feasible  to  perform  large-scale 
genome-wide  association  studies  (GWAS)  in  order  to 
systematically  search  for  other  low-  to  moderate-risk-
conferring  alleles  that  could  contribute  to  sporadic 
cutaneous melanoma (CM). In this review, we provide an 
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update on newly identified genetic variants associated with 
melanoma  risk,  pigmentation  phenotypes  such  as  skin 
color, hair color and sun sensitivity, and development of 
cutaneous nevi (CN) count. A recent article examining BCC 
is also considered, since susceptibility to melanoma may 
also result in high-risk predisposition to other such forms 
of cutaneous malignancies [12]
Risk variants of cutaneous malignancies
Association with pigmentation phenotype and risk of 
cutaneous melanoma
A comprehensive meta-analysis by Gandini and colleagues 
[13]  revealed  a  direct  link  between  pigmentation  and 
melanoma risk. There are more than 120 genes involved in 
regulating  pigmentation  status,  among  which  melano-
cortin-1-receptor (MC1R) is a key regulator. Many variants 
of  this  gene  sequence  are  implicated  in  melanoma  risk 
(reviewed  in  [14,15]).  MC1R  triggers  a  cAMP-dependent 
intracellular response that leads to the production of dark 
eumelanin in preference over red pheomelanin (Figure 1); 
eumelanin is thought to provide greater protection against 
ultraviolet radiation (UVR) than pheomelanin [16,17]. The 
presence of germline MC1R variants correlates with skin/
hair  color  and  poor  tanning  ability  (80%  in  individuals 
with  red  hair  color  (RHC)  and/or  fair  skin,  20%  in 
individuals with brown or black hair, and less than 4% in 
people with good tanning response) and increases CM risk 
by 3.9-fold [18]. Raimondi and colleagues [19] reviewed all 
MC1R variants and classified them based on RHC pheno-
type: (a) four ‘R’ MC1R variants (p.Asp84Glu, p.Arg151Cys, 
p.Arg160Trp,  and  p.Asp294His)  strongly  associated  with 
the  RHC  phenotype;  (b)  two  less  frequent  ‘R’  alleles  (p.
Arg142His  and  p.Ile155Thr)  based  on  strong  familial 
association with RHC phenotype; and (c) three ‘r’ alleles 
(p.Val60Leu, p.Val92Met, and p.Arg163Gln) with weaker 
association  with  the  RHC  phenotype.  Except  for  p.
Val60Leu  and  p.Val92Met,  all  other  variants  appear 
significantly  associated  with  melanoma  risk,  with  odds 
ratios (ORs) with a 95% confidence interval (CI) ranging 
from 1.42 (1.09 to 1.85) for p.Arg163Gln to 2.45 (1.32 to 
4.55)  for  p.Ile155Thr.  Two  studies  estimated  the 
penetrance  of  MC1R  variants  to  be  approximately  84% 
[20,21]. There is also some early evidence that MC1R status 
is  associated  with  BRAF  mutagenesis,  suggesting  a 
predisposition  to  develop  BRAF-driven  tumors  in 
individuals carrying these variants [22,23].
Another GWAS identified variants associated with hair and 
eye  pigmentation,  skin  sensitivity  to  sun  and  freckling 
among 2,986 Icelanders [24]. Shortly thereafter, the same 
group discovered another two coding variants in TPCN2 
(two-pore  segment  channel  2)  that  were  associated  with 
hair color, and a variant at the ASIP locus (which encodes 
the  Agouti  protein)  that  showed  strong  association  with 
sun  sensitivity,  freckling,  and  red  hair  -  phenotypic 
features similar to those in individuals carrying variants in 
MC1R  [25].  In  2008,  a  much  larger  study  examined  11 
SNPs  from  eight  pigmentation-associated  loci  (SLC24A4 
(solute  carrier  family  24),  KITLG  (KIT  ligand),  6p25.3, 
TYR  (tyrosinase),  OCA2  (oculocutaneous  albinism  II), 
TPCN2 (two-pore segment channel 2), ASIP (Agouti signal 
protein), TYRP1 (tyrosinase-related protein 1)) for CM and 
BCC  risk.  Three  cohorts  (810  individuals  with  CM  and 
36,723 non-CM controls from Iceland; 1,033 CM cases and 
2,650 controls from Sweden and 278 CM cases and 1,297 
controls from Spain) were tested for melanoma risk effects. 
A two-SNP haplotype was identified at the ASIP locus that 
showed strong association with CM (combined OR = 1.45; 
P  =  1.2  ×  10-9),  while  an  additional  non-synonymous 
coding variant in TYR (combined OR = 1.21; P = 2.8 × 10-7) 
and  a  non-coding  SNP  at  the  TYRP1  locus  were  also 
associated  significantly  with  melanoma  risk  (rs1408799; 
combined for all three samples, OR = 1.15; P = 0.00043) 
[26]. A second independent GWAS based in Australia also 
found evidence of a melanoma risk locus at the ASIP locus 
on chromosome 20q11 [27].
A  recent  GWAS  based  on  population  samples  collected 
across  European  populations  living  at  different  latitudes 
has  uncovered  additional  melanoma  risk  loci  with 
suggestive  biological  consequences  [28],  although  these 
are yet to be validated. The result was a joint effort from 
ten GenoMEL groups with 1,650 cases and 1,065 controls. 
The team identified five loci on chromosomes 2, 5, 9, 11 
and 16, with at least one SNP at each locus with genome-
wide significance (P < 5 × 10-7). Three of these loci were 
replicated in an independent cohort of 1,163 cases and 903 
controls.  The  strongest  association  was  seen  in  chromo-
some  16q,  with  one  new  SNP  (rs8059973,  OR  =  0.74), 
which  was  different  from  two  other  previously  reported 
SNPs on the same locus with association to hair color and 
skin  pigmentation  (rs258322,  rs4785763)  [29].  The 
rs8258322 SNP (OR (95% CI) = 1.16 × 10-12 to 2.54 × 10-27) 
was comparable to the MC1R variant previously described 
[21]  in  terms  of  increased  cutaneous  melanoma  risk, 
though the location of the SNP is distant from the MC1R 
locus per se. In addition, a chromosome 11 SNP near the 
TYR gene showed evidence of association with melanoma 
(rs1393350; P = 2.41 × 10-4). A third region on chromosome 
9p21 also showed significant association with melanoma. 
The implicated SNP (rs7023329, P = 4.03 × 10-7) is near, 
but distinct from, the high-risk CDKN2A locus; it appears 
to be more physically aligned with the methylthioadenosine 
phosphorylase  (MTAP)  gene  that  flanks  the  CDKN2A 
region.  These  novel  loci  will  be  a  key  addition  to  the 
pigmentation  variants  of  TYR  previously  identified  by 
deCODE genetics [26].
The  GWAS  analyses  also  uncovered  some  risk  variants 
whose  genetic  interactions  are  more  complex.  Interest-
ingly, in the large Icelandic-based GWAS, MC1R variants 
conferred  little  or  no  increased  risk  of  CM  among  the 95.3
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Icelandic population, whereas significant risks for CM were 
observed in both the Swedish and Spanish cohorts [25]. 
These findings suggest that RHC variants are not the only 
genetic risk factors for melanoma in the Icelandic cohort. 
This is consistent with an earlier study showing that some 
MC1R  variants  conferred  melanoma  risk  but  were  not 
associated with hair and skin color phenotypes [21]. Table 1 
summarizes  the  known  relationships  between  various 
GWAS  loci  and  their  associated  pigmentary  and  cancer 
phenotypes.
Variants associated with risk of basal cell carcinoma
BCC is the most common cancer and is sporadic in nature, 
although inherited forms have been described in the case 
Figure 1
An illustration of the MC1R pigmentation pathway and the loci implicated in melanoma risk. The binding of melanocortin-stimulating hormone 
(α-MSH) to its transmembrane receptor, Melanocortin-1-receptor (MC1R), results in stimulation of adenylate cyclase (AC) to produce cAMP. 
An antagonist to α-MSH, called Agouti protein (encoded by ASIP loci), inhibits this interaction. The release of cAMP in the cytoplasm 
activates the melanosomal enzymes, including tyrosinase (TYR) and tyrosinase-related protein-1 (TYRP-1), on the cell membrane of the 
melanosomes, resulting in a shift of pigment synthesis from pheomelanin to eumelanin. The variants of the genes encoding these proteins 
are listed. The corresponding odds ratio represents the risk of developing melanoma in patients carrying these variants.
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of nevoid basal cell carcinoma syndrome (NBCCS). This is 
characterized by rapid development of numerous BCCs in 
young  patients,  with  a  median  age  of  20  years  [30,31]. 
Susceptibility  to  BCC  has  been  shown  to  be  strongly 
associated with variants on chromosomes 1p36, 1q42, and 
5p15 [32]. Notably, some of the sequence variants respon-
sible for BCC appear to be independent of pigmentation 
traits;  in  fact,  the  5p15  variant  at  the  TERT-CLPTM1L 
(telomerase reverse transcriptase-cleft lip and palate trans-
membrane  1-like)  locus  is  protective  against  melanoma. 
The deCODE group also identified three SNPs associated 
with  non-melanoma  skin  cancer  but  not  melanoma  or 
pigmentation: (a) rs11170164 in the keratin 5 (KRT5) gene 
with a G138E substitution (combined OR 1.35, P = 2.1 × 10-9) 
conferring susceptibility to BCC; (b) rs2151280 on chromo-
some 9p21 near the CDKN2A/B locus; and (c) rs157935 on 
chromosome 7q32 [12].
Risk variants for cutaneous nevi
Melanocytic  nevi  (or  ‘moles’)  represent  both  precursors 
and  markers  of  melanoma  risk  [33,34].  The  genetics  of 
melanocytic nevus formation appear to be related to, but 
distinct  from,  CM  development.  A  meta-analysis  of  46 
different studies related to nevus formation and melanoma 
risk showed that a high mole count (101 to 120) increased 
the  relative  risk  (RR)  of  melanoma  by  about  seven-fold 
(RR = 6.89; 95% CI) when compared to a low nevus count 
(0 to 15). In a parallel estimate, the RR was over six times 
higher between the presence of five atypical moles and no 
moles at all (RR = 6.52; 95% CI) [33]. These studies clearly 
highlight that an increase in nevus count may indicate a 
genetic predisposition to melanoma but that environmental 
factors such as UV exposure and the deregulation of genes 
at  particular  signaling  pathways  could  potentiate  this 
effect. Subsequent studies have linked a high nevus count 
to the two melanoma loci on chromosome 9 including the 
CDKN2A  region  [35,36].  Recently,  a  large  GWAS  was 
conducted on mole count using 297,108 SNPs in a cohort 
of 1,524 twins from the TwinsUK registry, with subsequent 
validation  in  an  independent  European  cohort.  The 
strongest association was reported for a SNP in the MTAP 
locus next to CDKN2A on chromosome 9p21 (rs4636294, 
combined  P  =  3.4  ×  10-15).  Another  SNP  on  22q13.1 
(rs132985,  OR  =  1.23)  also  showed  a  strong  replicated 
signal (P = 2.6 × 10-7) [37]. It is intriguing to note that 9p21 
loci also harbor SNPs that have been implicated in both 
susceptibility  to  BCC  and  association  to  pigmentation 
phenotypes  as  described  above  [12,28].  The  associated 
SNP  on  chromosome  9p21,  rs  7023329,  which  was 
reported  in  the  Bishop  et  al.  study  [28],  has  also  been 
reported in this study. Furthermore, the 9p21 locus also 
harbors strong-risk SNPs for cardiac disease and type II 
diabetes. The biological relationship between these SNPs 
and  different  disorders  remains  a  source  of  intense 
investigation.
Summary
Large-scale  GWASs  have  identified  a  large  number  of 
moderate-  to  low-risk  melanoma  variants  in  different 
cohorts over the past few years. The information gained 
Table 1
GWAS loci and the associated pigmentary and cancer phenotypes
Chromosomal region/locus (SNP region) [Reference]  Pigmentation status  Cancer phenotype
MC1R (RHC, NRHC) multiple SNPs [18,19,28]  Blonde/red hair, freckling  Skin sensitivity, CM, BCC
TYR (rs1126809, rs1042602, rs1393350) [24,26,28,29]  Blue versus green eyes, freckling  Skin sensitivity, CM, BCC
TYRP1 (rs1408799) [25,26]  Blonde hair (weak), brown eyes, green eyes (weak)  CM
ASIP haplotype (rs1015362[G], rs4911414[T]) [25,26]  Red and blonde hair, Freckling  CM, BCC, skin sensitivity 
TPCN2 (rs35264875[T], rs3829241[A]) [25]  Blonde hair versus brown  CM and BCC (weak)
SLC24A4 (rs12896399) [24]  Blonde hair, green eyes brown eyes (weak)  Skin sensitivity (weak)
KITLG (rs12821256) [24]  Blonde hair  Not known
6p25.3 (rs1540771) [24]  Blonde hair, freckling  Skin sensitivity (weak)
OCA2 (rs1667394, rs7495174) [24]  Blonde hair, green and brown eyes  Skin sensitivity (weak)
9p21 adjacent to MTAP (rs7023329) [28]   Blonde hair, green and brown eyes, freckling  Skin sensitivity, CM
9p21 adjacent to CDKN2A/B [12]  No association  BCC, no association to CM
KRT5, G138E substitution [12]  No association  BCC, no association to CM
7q32 adjacent to KLF14 [12]  No association  BCC, no association to CM
MTAP rs4636294 ref [37]  Not known  CM
PLA2G6 (rs2284063) [37]  Not known  CM
BCC, basal cell carcinoma; CM, cutaneous melanoma; NRHC, non-red hair color variants; RHC, red hair color variants.95.5
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from  these  studies  advances  melanoma  risk  prediction 
more than ever. Although interesting in its own right, the 
GWAS results are unlikely to impact clinical management 
at  the  current  time.  Lower-risk  alleles  compete  against 
other  behavioral  risk  factors  that  may  modulate  one’s 
overall likelihood of developing melanoma and other forms 
of skin cancer. It is also somewhat ironic that high-power 
genetic approaches have recovered strong allelic signals in 
pathways  that  dictate  pigmentation  -  a  phenotype  well 
known for decades to confer cancer risk. The recent harvest 
of GWAS analyses provides a fundamental element for risk 
prediction  but  further  research  is  needed.  Commercial 
interest in utilizing GWAS results should be viewed with 
some trepidation, as it may lead to a false sense of security, 
or anxiety. However, the promise of this new information 
is  a  clearer  explanation  of  gene-gene  and  gene-environ-
ment interactions that will undoubtedly emerge over the 
next decade.
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